the Predictive Value of Immune Cell in Locally Advanced Cervical Cancer
Conditions: Locally Advanced Cervical Carcinoma; Concurrent Chemoradiotherapy; Immunotherapy Interventions: Radiation: Nab-paclitaxel/Platinum, Sintilimab Sponsors: RenJi Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 23, 2024 Category: Research Source Type: clinical trials
Early Detection of Complications During Immunotherapy for Haematological Malignancy
Conditions: Hematologic Cancer; CRS - Cytokine Release Syndrome Interventions: Device: WARD Sponsors: Rigshospitalet, Denmark Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
Irreversible Electroporation & Pembro Immunotherapy in Locally Advanced Pancreatic Cancer
Conditions: Pancreatic Cancer; Locally Advanced Pancreatic Cancer Interventions: Drug: Pembrolizumab; Device: Irreversible Electroporation Sponsors: H. Lee Moffitt Cancer Center and Research Institute; Angiodynamics, Inc. Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 22, 2024 Category: Research Source Type: clinical trials
HAIC Combined With PD-L1 Plus Regorafenib in the Treatment of Advanced Hepatocellular Carcinoma After Immunotherapy Failure
Conditions: HCC - Hepatocellular Carcinoma Interventions: Drug: PD-L1 inhibitor: Adebrelimab Injection ；Regorafenib Tablets Sponsors: Yehua Shen Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 19, 2024 Category: Research Source Type: clinical trials
Early Immunotherapy With Intravenous Immunoglobulin, Cyclophosphamide and Methylprednisolone in Patients With Anti-Hu-associated Paraneoplastic Sensory Neuronopathy
Conditions: Paraneoplastic Sensory Neuronopathy Interventions: Drug: Immunoglobulins IV (CLAYRIG); Drug: Cyclophosphamide IV; Drug: Methylprednisolone IV Sponsors: Assistance Publique - H ôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 18, 2024 Category: Research Source Type: clinical trials
Newly Emerging Immunotherapy for Pancreatic Cancer Treatment
Conditions: Pancreatic Cancer Interventions: Drug: JS001; Drug: JS004; Drug: JS007; Drug: JS015; Drug: Irinotecan Liposome Injection; Drug: 5-Fluorouracil (5-FU); Drug: Leucovorin (LV); Drug: Nab paclitaxel; Drug: Gemcitabine Sponsors: Fudan University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Neo-Sequence 2 ：NCT Plus Anti-angiogenesis Therapy and Immunotherapy for LADGC
Conditions: Gastric Cancer; Diffuse Type Carcinoma Interventions: Drug: Albumin paclitaxel+SOX+BEV+ PD-1 monoclonal antibody therapy Sponsors: Cancer Institute and Hospital, Chinese Academy of Medical Sciences Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 17, 2024 Category: Research Source Type: clinical trials
Safety and Immunogenicity of Innocell Autologous Cellular Immunotherapy in Recurrent Epithelial Ovarian Cancer
Conditions: Ovarian Cancer Interventions: Biological: Innocell Autologous Cellular Immunotherapy Sponsors: PhotonPharma, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 16, 2024 Category: Research Source Type: clinical trials
Anti-CD19 Chimeric Antigen Receptor T-Cell Immunotherapy for Chronic Lymphocytic Leukemia (CLL)
Conditions: B-Cell Chronic Lymphocytic Leukemia; Leukemia, Lymphocytic, Chronic, B-Cell; B-Lymphocytic Leukemia, Chronic Interventions: Biological: Autologous HuCD19 ( Anti-CD19)CAR T cells; Drug: Cyclophosphamide; Drug: Fludarabine; Drug: Rituximab Sponsors: National Cancer Institute (NCI) Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial for First-line Treatment of Hepatocellular Carcinoma
Conditions: Hepatocellular Carcinoma Interventions: Biological: γδ T cells; Drug: Targeted drugs; Drug: PD-1 monoclonal antibody Sponsors: Beijing 302 Hospital; Chinese Academy of Medical Sciences; Beijing GD Initiative Cell Therapy Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
Allogeneic Gamma-delta T Cells Combined With Targeted Therapy and Immunotherapy in a Phase 1 Clinical Trial of Hepatocellular Carcinoma Resistant to PD-1 Monoclonal Antibody
Conditions: Hepatocellular Carcinoma Interventions: Biological: γδ T cells; Drug: PD-1 monoclonal antibody; Drug: targeted drugs Sponsors: Beijing 302 Hospital; Chinese Academy of Medical Sciences; Beijing GD Initiative Cell Therapy Technology Co., Ltd. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 15, 2024 Category: Research Source Type: clinical trials
A Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.
Conditions: Metastatic Cancer Interventions: Radiation: Stereotactic Radiotherapy Sponsors: Elsan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
PSMA Therapy and Immunotherapy in Kidney Cancer
Conditions: Metastatic Renal Cell Carcinoma; Metastatic Clear Cell Renal Cell Carcinoma Interventions: Drug: Pembrolizumab; Drug: 177Lu-PNT2002; Drug: (F-18)-DCFPyL Sponsors: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Merck Sharp& Dohme LLC; Lantheus Medical Imaging Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Pilot Study to Assess the Ability of Stereotactic Radiotherapy to Restore the Efficacy of Immunotherapy in Patients With Metastatic Cancer.
Conditions: Metastatic Cancer Interventions: Radiation: Stereotactic Radiotherapy Sponsors: Elsan Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
Toripalimab With or Without Lenvatinib or Chemotherapy in First-Line Treatment of Advanced Biliary Tract Cancer
Conditions: Biliary Tract Neoplasms Immunotherapy Interventions: Drug: Toripalimab; Drug: Lenvatinib; Drug: Gemox Chemotherapy （Gemox or GC） Sponsors: Peking Union Medical College Hospital Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 12, 2024 Category: Research Source Type: clinical trials
